Safos, 1995 - Google Patents
Enzyme replacement therapy in ENU2 phenylketonuric mice using oral microencapsulated phenylalanine ammonia-lyase: a preliminary reportSafos, 1995
- Document ID
- 4406036943006181131
- Author
- Safos S
- Publication year
- Publication venue
- Artificial Cells, Blood Substitutes, and Biotechnology
External Links
Snippet
The presence of an extensive enterorecirculation of amino acids between the intestine and the body1 allows the removal of systemic phenylalanine in PKU rats by oral microencapsulated phenylalanine ammonia lyase2. The work presented in this article has …
- 108091022057 Phenylalanine Ammonia-Lyase 0 title abstract description 8
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fellman et al. | Soluble and mitochondrial forms of tyrosine aminotransferase. Relation to human tyrosinemia | |
Safos | Enzyme replacement therapy in ENU2 phenylketonuric mice using oral microencapsulated phenylalanine ammonia-lyase: a preliminary report | |
Martini et al. | Lactose digestion by yogurt beta-galactosidase: influence of pH and microbial cell integrity | |
US9637729B2 (en) | Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides | |
Kreis et al. | Biological effects of enzymatic deprivation of L-methionine in cell culture and an experimental tumor | |
Sanguansermsri et al. | Polyamines in human and cow’s milk | |
Lew et al. | Net synthesis of ATP by reversal of the sodium pump | |
JP2011063597A (en) | Oxalate-degrading microorganism or oxalate-degrading enzyme for preventing oxalate-related disease | |
EP0317355A2 (en) | Dietary compositions and methods using bile salt-activated lipase | |
Sassa et al. | Studies in porphyria. IV. Expression of the gene defect of acute intermittent porphyria in cultured human skin fibroblasts and amniotic cells: prenatal diagnosis of the porphyric trait. | |
CN111166742A (en) | Application of vitamin E in treatment of functional mutation of glutamate dehydrogenase | |
Hayasaka et al. | Nonketotic hyperglycinemia: two patients with primary defects of P-protein and T-protein, respectively, in the glycine cleavage system | |
WO1997026903A1 (en) | Microencapsulated genetically engineered microorganisms for clinical application | |
Anderson et al. | Porphobilinogen deaminase: methods and principles of the enzymatic assay | |
WO2000057871A2 (en) | Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof | |
Barger | Physiological chemistry | |
CN116355815B (en) | Bacillus licheniformis for degrading arginine and application thereof | |
US20240175039A1 (en) | Engineering probiotic for degrading uric acid, and construction method therefor and use thereof | |
Stein et al. | The effect of trauma on protein synthesis | |
Inoue et al. | Entrapment of phenylalanine ammonia-lyase in silk fibroin for protection from proteolytic attack | |
Bartlett et al. | Studies on cultured fibroblasts from patients with defects of biotin-dependent carboxylation | |
de Freitas et al. | New approaches to the treatment of phenylketonuria | |
CN118001407B (en) | Application of PAD2 in preparation of medicines for treating ischemic hypoxic malignant arrhythmia | |
Bourget | The effects of phenylalanine ammonia-lyase immobilized within artificial cells on the compartmental distribution of amino acids in phenylketonuric rats | |
Safos | Phenylketonuria: enzyme replacement therapy using microencapsulated phenylalanine ammonia-lyase |